drugset
drugset / Trial / NCT01638104

ANX-042 Healthy Volunteer Dose Escalation Study

NCT01638104 ↗

Phase 1 Completed 30 enrolled Mayo Clinic Anexon, Incorporated · collabCelerion · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study was to investigate the safety and tolerability of ANX-042 when administered by continuous intravenous (IV) infusion in healthy volunteers.

Timeline

Start
2012-08
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX-042 Peptide 0.001 ug/kg Intravenous
Subject ANX-042 Peptide 0.003 ug/kg Intravenous
Subject ANX-042 Peptide 0.0065 ug/kg Intravenous
Subject ANX-042 Peptide 0.01 ug/kg Intravenous
Subject ANX-042 Peptide 0.03 ug/kg Intravenous
Subject ANX-042 Peptide 0.1 ug/kg Intravenous
Subject ANX-042 Peptide 0.3 ug/kg Intravenous

Indications

No indication recorded.